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Abstract 
Introduction 
Non-adherence to secondary preventative medications after stroke is common and is 
associated with poor outcomes. Numerous strategies exist to promote adherence.  We 
performed a systematic review and meta-analysis to describe the efficacy of strategies to 
improve adherence to stroke secondary prevention. 
Methods 
We created a sensitive search strategy and searched multiple electronic databases 
(MEDLINE, EMBASE, CINAHL, PsycINFO, CENTRAL, and Web of Knowledge) for 
studies of interventions that aimed to enhance adherence to secondary preventative 
medication after stroke. We assessed quality of included studies using the Cochrane tool for 
assessing risk of bias. We performed narrative review and performed meta-analysis where 
data allowed. 
Results 
From 12,237 titles, we included seventeen studies in our review. Eleven studies were 
considered to have high risk of bias, 3 with unclear risk and 3 of low risk. Meta-analysis of 
available data suggested that these interventions improved adherence to individual 
medication classes (blood pressure lowering drugs - OR, 2.21; 95% CI (1.63, 2.98), 
[p<0.001], lipid-lowering drugs - OR, 2.11; 95% CI (1.00, 4.46), [p=0.049], and anti-
thrombotic drugs – OR, 2.32; 95% CI (1.18, 4.56, [p=0.014]) but did not improve adherence 
to an overall secondary preventative medication regimen (OR, 1.96; 95% CI (0.50, 7.67), 
[p=0.332]). 
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Conclusion 
Interventions can lead to improvement in adherence to secondary preventative medication 
after stroke. However, existing data is limited as several interventions, duration of follow-up, 
and various definitions were used. These findings need to be interpreted with caution. 
Keywords: Stroke, TIA, secondary, prevention, intervention, adherence. 
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Introduction 
A variety of evidence based pharmacological strategies are recommended to reduce the risk 
of stroke recurrence. The exact medications used will differ dependent on stroke aetiology 
and typically include anti-thrombotic(1-4), blood pressure lowering(4-7) and lipid 
lowering(4, 8, 9) strategies for ischaemic stroke and blood pressure lowering(5, 10) strategies 
for haemorrhagic stroke. It is recognised that adherence to secondary preventative 
medications after stroke is variable; in some studies more than half of participants stopped 
taking their prescribed drugs 1 year after the stroke incident(11). 
There are many phrases used to describe the process of patients taking medication according 
to a prescribed schedule, for example adherence, compliance, concordance.  For consistency 
we will use the term medication adherence throughout the review.  We recognise that this 
descriptor is problematic but there is no preferred terminology and medication adherence is 
the phrase often used in the scientific literature. 
Several interventions have been tested to improve adherence to prescribed medication, thus, a 
specific review of this area was required. We performed a systematic review and meta-
analysis of interventions designed to improve adherence to preventative medications in 
patients with stroke.  
Methodology 
We conducted a systematic review and followed the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines(12). The review protocol was registered in 
PROSPERO (registration number, CRD42015027529). 
Search Strategy and Study Selection 
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We created lists with all identifiable synonyms for “Stroke” and “Medication Adherence” 
(available in the supplementary materials). Then, two independent reviewers (SA and WD) 
searched MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCOhost), PsycINFO 
(EBSCOhost), CENTRAL (Cochrane Library), and Web of Knowledge (Thomson Reuters). 
We also reviewed reference lists of included studies and relevant reviews to identify further 
studies.  We continued the process until no further papers were identified. 
Eligibility Criteria 
We included interventional studies published in English. Abstracts of unpublished papers 
were excluded. Studies had to include adult participants (aged 18 years or more) who had 
previously suffered stroke or transient ischaemic attack (TIA) and who were prescribed 
medication for the prevention of recurrent stroke. We defined preventative medications as 
any antiplatelet, anticoagulant, blood pressure lowering or lipid lowering drugs. Studies had 
to report a measure of medication adherence as an outcome. We recognised that many 
interventions can potentially impact on adherence.  We were inclusive and accepted any 
study where the authors’ stated primary aim was to improve adherence.  We accepted any 
control, including usual care and sham interventions. Where disagreement arose regarding 
study eligibility, a third party review (JD) and consensus meeting was arranged.  
Assessment of Risk of Bias 
We used the Cochrane tool for assessing risk of bias which is a domain-based evaluation tool 
for parallel-group trials(13) and modified to fit the few studies where an alternative design 
was used. Two reviewers (SA and JD) independently assessed risk of bias and met to discuss 
and finalise the assessment where disagreement arose. We considered studies as of high 
overall risk of bias if they did not meet the criteria specified for more than two key domains 
(selection, performance or detection bias). Moreover, given the nature of the studies we 
6 
 
acknowledged that blinding of the participant was rarely practical so we did not judge studies 
as of high risk of bias based on blinding only. 
Narrative Review and Statistical Analysis 
We described study characteristics and interventions using narrative review. Where possible, 
effect and sample size for outcomes relating to medication adherence were extracted and 
combined within a meta-analysis to derive an odds ratio and 95% confidence interval (CI) for 
the effect of the intervention.  Forest plots were constructed for each analysis (overall 
medication, blood pressure-lowering drugs, lipids-lowering drugs and anti-thrombotic 
medication each in a separate analysis). Studies included in the overall medication analysis 
were those that assessed the effect of an intervention on the adherence to entire medication 
regimen prescribed after stroke. We have assessed heterogeneity using Higgin I
2 
(13) and 
repeated analyses where heterogeneity was detected with one study removed. We assessed 
for publication bias using funnel plots (available in supplementary appendix). Comprehensive 
Meta-Analysis (CMA, version 2.0, Biostat Inc, Englewood, New Jersey, US) software was 
used for all analyses. 
Results 
The search encompassed the literature up to an including April 2014 and identified a total of 
12,237 titles. Title review identified 143 papers for abstract review. Of these 57 were 
retrieved for full-text review. We identified 17 of these as meeting our eligibility criteria 
(figure 1). The completed PRISMA Checklist is available in supplementary materials.  
Narrative Review 
Description of Eligible Studies 
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The 17 included studies were prospective interventional studies published between 2004 and 
2014, of which 8 used a single group (pre- and post-intervention) design(14-21) and 9 
compared two groups(22-30). Details of study characteristics and interventions can be found 
in table 1. 
The total number of participants enrolled into the included studies was 3942 with stroke/TIA. 
Of these, 2090 participants were in an intervention group and 824 participants were controls. 
Details of participants can be found in the supplementary materials. 
Description of Interventions 
Interventions were educational and motivational as described in 6 studies(20, 23-25, 27, 29). 
Patients were prescribed medication and educated about it while in-patient not in primary 
care in three studies(19-21). Three studies targeted simplification of drug regimen(14, 15, 
26), two of which provided dosettes(15, 26). One study provided environmental cues or 
reminders together with reducing concerns and misbeliefs regarding medications(28). Five 
studies used programs of combined interventions to enhance risk factor management after 
stroke (e.g. STOP Program(22); PROTECT Program(16-18); STOP stroke Program(30)). 
Secondary Preventative Drug Classes 
Ten studies assessed adherence to anti-thrombotics(14, 16-18, 20, 21, 23, 25, 27, 30), ten 
looked at anti-hypertensive medications(15-18, 20, 24, 25, 27, 28, 30), ten studies explored 
lipid-lowering drugs(15-20, 23, 25, 27, 30) and seven looked at adherence to the overall 
medications regimen(21-23, 26-29). 
Method of Assessing Adherence to Medications 
Ten studies used a subjective measure only (telephone or face-to-face interviews, or 
questionnaires)(14, 16-18, 20-22, 24, 29, 30). Two studies used an indirect measure where 
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Primary Care Physician was contacted in one(23) and the other used measurement of blood 
pressure and cholesterol(25). Remaining five studies used mixed methodology to assess 
medication adherence (i.e. subjective and objective measures)(15, 19, 26-28). 
Efficacy of Interventions 
Interventions used in 3 studies were beneficial and resulted in statistically significant 
improvement in medication adherence(16, 23, 29). The interventions of 3 other studies were 
helpful in improving adherence but not to all measured adherence aspects(15, 20, 28) and the 
interventions in 4 studies were neutral and resulted in no difference between groups(24, 26, 
27, 30). 
Beneficial Interventions 
Interventions that involved patient counselling and education at discharge improved 
adherence to antithrombotic drugs (83.8% control vs. 91.9% intervention [P=0.033]), statins 
(69.8% control vs. 87.7% intervention [P<0.001]) and the overall regimen (83.3% control vs. 
90.9% intervention [P=0.01])(23).  A study adopted an educational program to manage risk 
factors after patient discharge and that resulted in a statistically significant improvement in 
adherence to antihypertensive (from 61.7% to 77.6%), antiplatelet (from 50.1% to 95.7%) 
and lipid-lowering drugs (from 39.8% to 81.2%) [all p values <0.05](16). Another study 
encouraged self-care after stroke which resulted in a statistically significant improvement in 
medication adherence between intervention (p<0.001) and control group (p=0.293)(29). 
A motivational intervention piloted to support health behaviour change was statistically 
significant in improving medication adherence (25% non-adherers before vs. 15% after 
intervention [p=0.003])(15) but not adherence reported by pharmacist. Another study 
assessed rate of medication adherence using electronic medication monitoring and provided 
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environmental cues as reminders to take medications(28). Medication adherence using the 
MARS questionnaire improved by a mean difference: 0.61; 95% CI (0.1, 1.2) [p=0.027]). 
This intervention also resulted in improved rate of taking doses as scheduled (mean 
difference: 9.8%; 95% CI (0.2, 16.2) [p=0.048]) but not total doses taken nor days when 
correct dose taken. Patients in another study were initiated therapy with secondary 
preventative medication at discharge and educated regarding their medication then followed-
up annually(20). This intervention resulted in a statistically significant persistence to 
antihypertensive (from 58% at discharge to 74% 10 years after stroke) and lipid-lowering 
drugs (21% to 48%) but declined persistence for antithrombotic drugs (from 92% to 78%) (all 
p values <0.001). 
Interventions with No Difference 
A motivational and educational intervention in one of the studies was not effective in 
improving medication compliance (99% control versus 98% intervention [p=0.496])(24). 
Another study that targeted blood pressure management after stroke did not differ in 
medication self-efficacy (p=0.28), number of missed pills (p=0.95), or adherence reported by 
community pharmacist (p=0.15)(26). STOP Stroke Program was a motivational intervention 
to modify patients’ and caregivers’ behaviour after stroke but resulted in no difference in 
patients’ adherence to medication(30). Researchers in another study adopted a behaviour 
modification technique and this intervention did not improve adherence rate to antiplatelet 
drugs (p=0.28), antihypertensive drugs (p=0.81) or statins (p=0.92)(27). 
The remaining seven studies(14, 17-19, 21, 22, 25) did not report the significance level of 
their intervention in quantitative terms although(17-19, 21, 22) claimed the intervention was 
effective in improving medication adherence. The supplementary materials contains more 
details of outcomes. 
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Risk of Bias across Included Studies 
Eleven studies were felt to be of high risk mainly because of selection, performance or 
detection bias(14-21, 23, 28, 29). Nine studies were non-randomised or did not follow an 
adequate randomisation method(14-21, 29). Eleven did not mask participants’ allocation(14-
21, 23, 28, 29). Participants and personnel were not blinded in thirteen(14-21, 23, 24, 28-30) 
and the outcome assessors were not blinded in eight studies(14, 16-19, 21, 23, 28). Fifteen 
studies used a subjective method to monitor adherence five of which combined it with other 
measures, this self-reported adherence is questionable as it is subject to bias and reported to 
overestimate adherence(31, 32). More details on other sources of bias in included studies are 
available in the supplementary materials. 
Meta-Analysis 
We separated findings of included studies depending on secondary preventative medication 
classes reported (table 2). Four studies were included in the meta-analysis of studies reporting 
effect of intervention on adherence to the overall secondary preventative medications 
regimen after stroke(22, 23, 27, 28). This analysis showed a non-significant effect of 
intervention in included studies on adherence to the overall medication regimen (OR, 1.96; 
95% CI (0.50, 7.67), [p=0.332]). Higgin I
2
 indicated a substantial heterogeneity, so this 
analysis was performed with one study removed (27) as it was clearly weighting results 
(forest plot of resulted analysis in supplementary materials). Three studies were excluded 
from this analysis because two recorded changes in medication adherence based on 
questionnaire scores (i.e. no effect size measurement available but change in questionnaire 
scores only and used different scales) (26, 29) and one was non-controlled(21). 
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Six papers were included in the meta-analysis of studies reported adherence to blood-pressure 
lowering drugs; three of which used a matched group cohort(15, 16, 18) and three performed 
two-group analysis(24, 25, 27). This analysis showed a significant effect of intervention 
within studies used a matched group analysis (OR, 2.21; 95% CI (1.63, 2.98), [p<0.001]) but 
not those used unmatched groups (OR, 0.966; 95% CI (0.26, 3.59), [p=0.959]). Four studies 
were excluded from this analysis. One was non-controlled study(20), one only reported 
change in adherence in terms of questionnaire scores(28), one did not record effect size of 
intervention directly on medication adherence (30), and one(17) used the same population as 
another study already included in the analysis(18). 
Three studies were included in the meta-analysis of studies reported effect of intervention on 
adherence to lipid-lowering drugs(23, 25, 27). This meta-analysis showed a significant effect 
of interventions used in included studies on adherence to lipid-lowering drugs OR, 2.11; 95% 
CI (1.00, 4.46), [p=0.049]. Seven studies were excluded from this analysis; two were non-
controlled(19, 20), two lacked record of effect size of intervention on adherence(15, 30), and 
two studies used matched group analysis (16, 18) unlike included studies. Also, two 
studies(17, 18) analysed the same population so(17) was excluded.  
Two studies were included in the meta-analysis of studies reported effect of intervention on 
adherence to anti-thrombotic drugs(23, 27). This analysis has also shown a significant effect 
of used interventions on adherence to anti-thrombotic drugs OR, 2.32; 95% CI (1.18, 4.56, 
[p=0.014]). Eight studies were excluded from this analysis; three were non-controlled(14, 20, 
21), one used a matched group analysis(16) (unlike included studies), one did not record 
effect size of intervention on medication adherence(30) and two showed no change in 
adherence between groups(18, 25) (so no odds ratio could be calculated) and one(17) used 
the same population as(18) so was also excluded.  Forest-plots were constructed for each 
analysis (figure 2). 
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Discussion 
In this systematic review and meta-analysis we found that interventions that targeted risk 
factor control and encouraged self-care resulted in high continuation rate of secondary 
preventative medications after stroke. Interventions in six studies were shown to be 
potentially beneficial in maintaining higher continuation rate; many of which included an 
educational element which greatly influenced the importance of increasing patients’ 
awareness regarding their prescribed medication. 
A Cochrane review of interventions for risk factor control after stroke reported that 
educational or behavioural modification interventions were effective only as a part of a multi-
approach intervention(33). Only one study in this Cochrane review that improved medication 
adherence was of behavioural change nature (cues, reminders and medication routine) 
combined with an educational element. This study was included in the current review(28). 
We found that both interventions used, definition of adherence and duration of follow-up 
varied considerably and that limited the validity of the benefit suggested by this review. The 
Cochrane review similarly reported huge heterogeneity of used interventions and reporting of 
outcomes and only produced a qualitative analysis with regards to adherence to secondary 
preventative medication. 
Interventions that implemented change in practice, involved regimen modification or 
simplification, introduced environmental cues, or provided reminders or dosettes were 
usually effective in maintaining therapy with secondary preventative medications. Also, 
integrated care interventions that focused on risk factors management resulted in a high rate 
of adherence to secondary preventative medications after stroke. Another Cochrane review of 
interventions to improve medication adherence(34) reported that to be relatively efficient, 
interventions needed to be of a complex nature but effect was still modest. 
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In our narrative synthesis, we found that the majority of published studies suggested efficacy 
in improving adherence. This is an encouraging signal but in the absence of a formal meta-
analysis we prefer not to interpret this finding as a definitive evidence of efficacy. We could 
only conclude that some interventions suggest a potential benefit and these were usually 
focused on increasing patients’ awareness in addition to introducing behavioural change in 
order to enhance medication adherence. Given the shared features of these interventions, a 
further evaluation in larger samples would allow for more robust conclusion regarding which 
intervention would be most useful for patients with stroke. 
Limitations 
There were several limitations of this systematic review and meta-analysis. Data on 
interventions to enhance medication adherence after stroke was very limited and 
heterogeneous. Moreover, reporting of medication adherence is not universal (various scales, 
methodology e.g. subjective vs. objective) and studies that used questionnaires were not 
standardised and each used a different scale. Furthermore, different definitions of medication 
adherence were used and there was variable use of terminology e.g. adherence, compliance. 
In addition, there is no standardised scale to critically appraise type of included studies. 
Strengths 
This is the first systematic review to evaluate interventions used to enhance adherence to 
secondary prevention medication in stroke population. For the purpose of this systematic 
review and meta-analysis we identified a comprehensive list of synonyms and used multiple 
search engines. Also, we used a wide search strategy this is so we do not mistakenly exclude 
studies. 
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Implication for Practice 
Additional focus should be given to stroke survivors as they are usually prescribed multiple 
agents, some with frequent daily dosing in order to reach their target blood pressure levels. 
Moreover, side effects can compromise adherence so if patients have such concerns, these 
need to be clarified. This analysis has also reflected the crucial role of education on 
medication changes at discharge on medication adherence. 
Conclusion 
Many interventions were simple and readily-available and were effective in maintaining 
therapy with secondary preventative medications. Future research should focus on methods to 
better prevent medication non-adherence. 
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Table 1: Characteristics of Intervention Studies 
Author Population 
Stroke 
Type 
Follo
w-up 
Secondary 
preventativ
e 
Method to 
monitor 
adherence 
Description of 
intervention 
Douen 
2008(14) 
Intervention=130 
Control=N/A 
Any stroke 
eligible for 
Anti-
platelet but 
not Anti-
coagulant 
therapy 
2 
weeks 
Aspirin  
Dipyridamo
le  
 
Subjective-
patient 
telephone 
interview 
 
Dosage 
modification & 
follow-up at 
week 1 & 2 
Evans-
Hudnall 
2014(22) 
Intervention=30 
Control=30 
Any stroke 4 
weeks 
Not 
specified 
Subjective-
patient 
telephone 
interview  
Secondary 
Stroke 
Prevention 
Program 
(STOP) = 3 
stroke self-care 
& goal-setting 
activities at 
baseline & 
follow-up at 4 
weeks 
Hohmann 
2013(23) 
Intervention=155 
Control=155 
Any stroke 3 
month
s 
Anti-
thrombotics  
Statins 
Overall 
regimen 
Indirect-via 
Primary 
Care 
Physician  
Education by 
clinical 
pharmacist at 
discharge 
Hornnes 
2011(24) 
Intervention=172 
Control=177 
Any stroke 1 year Anti-
hypertensiv
es  
Subjective-
patient 
interview 
Motivational, 
educational & 
home visits 
Ireland 
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Table 2: Record of studies included in meta-analyses 
Study name 
Intervention Control 
Effect size (%) N Effect size (%) N 
Overall secondary preventative drugs 
Evans-Hudnall 2014 25 (93) 27 15 (60) 25 
Hohmann 2013 133 (91) 146 112 (83) 135 
McManus 2009 29 (78) 37 36 (92) 39 
O’Carroll 2013 29 (99) 29 27 (94) 29 
Blood pressure lowering drugs 
Hornnes 2011 96 (98) 98 110 (99) 111 
Ireland 2010 17 (85) 20 16 (80) 20 
Maasland 2007 28 (92) 30 25 (92) 27 
McManus 2009 36 (97) 37 41 (95) 43 
Menard 2011 278 (78) 358 221 (62) 358 
Ovbiagele 2004 109 (84) 130 122 (94) 130 
Lipid-lowering drugs 
Hohmann 2013 121 (88) 138 90 (70) 129 
Maasland 2007 28 (93) 30 25 (93) 27 
McManus 2009 32 (88) 36 39 (89) 44 
Anti-thrombotic drugs 
Hohmann 2013 137 (92) 149 119 (84) 142 
McManus 2009 44 (96) 46 44 (88) 50 
N: total number of subjects 
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